Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro-Reference-Cited by-同舟云学术

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gammeltoft Karen A.¹²,Zhou Yuyong¹²,Duarte Hernandez Carlos R.¹²,Galli Andrea¹²^ORCID,Offersgaard Anna¹²,Costa Rui¹²,Pham Long V.¹²,Fahnøe Ulrik¹²,Feng Shan¹²,Scheel Troels K. H.¹²^ORCID,Ramirez Santseharay¹²^ORCID,Bukh Jens¹²^ORCID,Gottwein Judith M.¹²^ORCID

Affiliation:

1. Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark

2. Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their interactions with remdesivir, the only direct-acting antiviral approved for COVID-19 treatment.

Funder

Candys Foundation

Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat

Ministry of Science, Innovation and Higher Education | Danish Agency for Science and Higher Education

Novo Nordisk Fonden

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02680-20

Reference89 articles.